Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HealthTronics bids for EndoCare

This article was originally published in The Gray Sheet

Executive Summary

In a letter to Endocare's board of directors, released after the markets closed on Aug. 6, HealthTronics says it wants to buy the cryosurgery device company for $2.28 per share, about a 20% premium over Endocare's Aug. 6 closing stock price. Endocare responds that its board will review the unsolicited bid and consult with advisers. Both companies have a focus on prostate cancer. In second-quarter earnings released Aug. 6, Endocare's sales were flat at $7.9 million

You may also be interested in...



Endocare rejects acquisition bid

Cryocare prostate cancer cryoablation device developer Endocare rejects HealthTronics' unsolicited acquisition proposal, the company announces Aug. 13. HealthTronics, a urology service provider and device distributor, offered to pay $2.28 per share Aug. 6, but Endocare's board unanimously agreed the offer is inadequate (1"The Gray Sheet" Aug. 11, 2008, In Brief)

Crunch Time For Protection Of New Therapeutic Uses In Europe

The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.

Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.

UsernamePublicRestriction

Register

MT026441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel